A Real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia

Basit Öğe Kaydı
dc.authoridMehmet Hilmi Doğu / 0000-0001-7237-2637
dc.authorscopusidMehmet Hilmi Doğu / 55212747300
dc.authorwosidMehmet Hilmi Doğu / W-2255-2017
dc.contributor.authorGemici, Ali Ihsan
dc.contributor.authorÖzkalemkas, Fahir
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorAlacacıoğlu, İnci
dc.contributor.authorGüney, Tekin
dc.contributor.authorInce, Idris
dc.contributor.authorGedük, Ayfer
dc.date.accessioned2021-06-10T12:36:58Z
dc.date.available2021-06-10T12:36:58Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.en_US
dc.identifier.citationGemici, A., Ozkalemkas, F., Dogu, M. H., Tekinalp, A., Alacacioglu, I., Guney, T., ... & Sevindik, O. G. (2021). A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia.en_US
dc.identifier.doi10.1016/j.clml.2021.04.004en_US
dc.identifier.issn2152-2650en_US
dc.identifier.pmid34059487en_US
dc.identifier.scopus2-s2.0-85107154198en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.clml.2021.04.004
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1791
dc.identifier.wosWOS:000684596500017en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorDoğu, Mehmet Hilmi
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofClinical Lymphoma, Myeloma and Leukemiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.subjectBcl2en_US
dc.subjectInhibitoren_US
dc.subjectReal Lifeen_US
dc.subjectVenetoclaxen_US
dc.titleA Real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemiaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
66.pdf
Boyut:
568.95 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu